摘要 |
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC. |
申请人 |
MACROGENICS, INC.;STAVENHAGEN, JEFFERY;GORLATOV, SERGEY;RANKIN, CHRISTOPHER;TUAILLON, NADINE |
发明人 |
STAVENHAGEN, JEFFERY;GORLATOV, SERGEY;RANKIN, CHRISTOPHER;TUAILLON, NADINE |